SG11201807868VA - Transfected t-cells and t-cell receptors for use in immunotherapy against cancers - Google Patents

Transfected t-cells and t-cell receptors for use in immunotherapy against cancers

Info

Publication number
SG11201807868VA
SG11201807868VA SG11201807868VA SG11201807868VA SG11201807868VA SG 11201807868V A SG11201807868V A SG 11201807868VA SG 11201807868V A SG11201807868V A SG 11201807868VA SG 11201807868V A SG11201807868V A SG 11201807868VA SG 11201807868V A SG11201807868V A SG 11201807868VA
Authority
SG
Singapore
Prior art keywords
international
cells
present description
cell receptors
peptides
Prior art date
Application number
SG11201807868VA
Inventor
Leonie Alten
Dominik Maurer
Sebastian Bunk
Original Assignee
Immatics Biotechnologies Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Immatics Biotechnologies Gmbh filed Critical Immatics Biotechnologies Gmbh
Publication of SG11201807868VA publication Critical patent/SG11201807868VA/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/7051—T-cell receptor (TcR)-CD3 complex
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/14—Blood; Artificial blood
    • A61K35/17—Lymphocytes; B-cells; T-cells; Natural killer cells; Interferon-activated or cytokine-activated lymphocytes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/461—Cellular immunotherapy characterised by the cell type used
    • A61K39/4611—T-cells, e.g. tumor infiltrating lymphocytes [TIL], lymphokine-activated killer cells [LAK] or regulatory T cells [Treg]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/463—Cellular immunotherapy characterised by recombinant expression
    • A61K39/4631—Chimeric Antigen Receptors [CAR]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/463—Cellular immunotherapy characterised by recombinant expression
    • A61K39/4632—T-cell receptors [TCR]; antibody T-cell receptor constructs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/464—Cellular immunotherapy characterised by the antigen targeted or presented
    • A61K39/4643—Vertebrate antigens
    • A61K39/4644—Cancer antigens
    • A61K39/464484—Cancer testis antigens, e.g. SSX, BAGE, GAGE or SAGE
    • A61K39/464486—MAGE
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/464—Cellular immunotherapy characterised by the antigen targeted or presented
    • A61K39/4643—Vertebrate antigens
    • A61K39/4644—Cancer antigens
    • A61K39/464484—Cancer testis antigens, e.g. SSX, BAGE, GAGE or SAGE
    • A61K39/464488—NY-ESO
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/10—Processes for the isolation, preparation or purification of DNA or RNA
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C12N5/0636—T lymphocytes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/10—Cells modified by introduction of foreign genetic material
    • C12N5/12—Fused cells, e.g. hybridomas
    • C12N5/16—Animal cells
    • C12N5/163—Animal cells one of the fusion partners being a B or a T lymphocyte
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K39/46
    • A61K2239/46—Indexing codes associated with cellular immunotherapy of group A61K39/46 characterised by the cancer treated
    • A61K2239/55—Lung
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K39/46
    • A61K2239/46—Indexing codes associated with cellular immunotherapy of group A61K39/46 characterised by the cancer treated
    • A61K2239/57—Skin; melanoma
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2510/00—Genetically modified cells

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Zoology (AREA)
  • Cell Biology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Wood Science & Technology (AREA)
  • Mycology (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Hematology (AREA)
  • Developmental Biology & Embryology (AREA)
  • Virology (AREA)
  • Toxicology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Oncology (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)

Abstract

INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT) (19) World Intellectual Property -, Organization 11M1111101110101011111 HO 11111 0111310111111101011111001111101111 III N International Bureau .. .... ..Yejd .... ...,,, (10) International Publication Number (43) International Publication Date WO 2017/158103 Al 21 September 2017 (21.09.2017) WIP0 I PCT (51) International Patent Classification: (81) Designated States (unless otherwise indicated, for every C07K 14/435 (2006.01) C12N 15/09 (2006.01) kind of national protection available): AE, AG, AL, AM, A61K 35/12 (2015.01) C12N 15/10 (2006.01) AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, A61K 35/66 (2015.01) BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, (21) International Application Number: HN, HR, HU, ID, IL, IN, IR, IS, JP, KE, KG, KH, KN, PCT/EP2017/056260 KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, (22) International Filing Date: MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, 16 March 2017 (16.03.2017) NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, (25) Filing Language: English TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, (26) Publication Language: English ZA, ZM, ZW. (30) Priority Data: (84) Designated States (unless otherwise indicated, for every 1604492.7 16 March 2016 (16.03.2016) GB kind of regional protection available): ARIPO (BW, GH, 62/308,975 16 March 2016 (16.03.2016) US GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, (71) Applicant: IMMATICS BIOTECHNOLOGIES GMBH TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, [DE/DE]; Paul-Ehrlich-StraBe 15, 72076 Tiibingen (DE). DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, (72) Inventors: ALTEN, Leonie; WeiBdornweg 14, App. 161, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, 72076 Tubingen (DE). MAURER, Dominik; Fleinerweg SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, _ 7, 72116 Moessingen (DE). BUNK, Sebastian; Staeudach GW, KM, ML, MR, NE, SN, TD, TG). — 182, 72074 Tiibingen (DE). Published: _ (74) Agent: BOEHMERT & BOEHMERT; Jan B. KRAUSS, — with international search report (Art. 21(3)) = Pettenkoferstrasse 20 - 22, 80336 Munich (DE). — with sequence listing of description (Rule 5.2(a)) part = = = = = = = = = = 1-1 M (54) Title: TRANSFECTED T-CELLS AND T-CELL RECEPTORS FOR USE IN IMMUNOTHERAPY AGAINST CANCERS 0 1-1 (57) : The present description relates to T-cell receptors (TCRs) binding to tumor-associated antigens (TAAs) for targeting GC cancer cells, T-cells expressing same, methods for producing same, and methods for treating cancers using same. In particular, the L i ) present description relates to TCRs and their variants that bind to HLA class I or II molecules with a peptide, such as MAG-003 S have the amino acid sequence of KVLEHVVRV (SEQ ID NO:1). The present description further relates to peptides, proteins, nude- IL— is acids and cells for use in immunotherapeutic methods. In particular, the present description relates to the immunotherapy of can- 1-1 c:::: ) cer. The present description furthermore relates to tumor-associated T-cell peptide epitopes, alone or in combination with other to - N mor-associated peptides that can for example serve as active pharmaceutical ingredients of vaccine compositions that stimulate an - 0 ti-tumor immune responses, or to stimulate T-cells ex vivo and transfer into patients. Peptides bound to molecules of the major histo - compatibility complex (MHC), or peptides as such, can also be targets of antibodies, soluble T-cell receptors, and other binding mo - 5. lecules.
SG11201807868VA 2016-03-16 2017-03-16 Transfected t-cells and t-cell receptors for use in immunotherapy against cancers SG11201807868VA (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201662308975P 2016-03-16 2016-03-16
GBGB1604492.7A GB201604492D0 (en) 2016-03-16 2016-03-16 Transfected t-cells and t-cell receptors for use in immunotherapy against cancers
PCT/EP2017/056260 WO2017158103A1 (en) 2016-03-16 2017-03-16 Transfected t-cells and t-cell receptors for use in immunotherapy against cancers

Publications (1)

Publication Number Publication Date
SG11201807868VA true SG11201807868VA (en) 2018-10-30

Family

ID=55952417

Family Applications (1)

Application Number Title Priority Date Filing Date
SG11201807868VA SG11201807868VA (en) 2016-03-16 2017-03-16 Transfected t-cells and t-cell receptors for use in immunotherapy against cancers

Country Status (16)

Country Link
US (1) US10538573B2 (en)
EP (1) EP3430030B1 (en)
JP (1) JP7340127B2 (en)
KR (2) KR102457504B1 (en)
CN (1) CN108884136B (en)
AU (2) AU2017235467B2 (en)
CA (1) CA3017502A1 (en)
CR (1) CR20180492A (en)
EA (1) EA201892021A1 (en)
GB (1) GB201604492D0 (en)
MA (2) MA43330B1 (en)
MX (1) MX2018011225A (en)
MY (1) MY189042A (en)
SG (1) SG11201807868VA (en)
TW (1) TWI764886B (en)
WO (1) WO2017158103A1 (en)

Families Citing this family (63)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2943498T3 (en) 2013-08-05 2023-06-13 Twist Bioscience Corp de novo synthesized libraries
WO2016126882A1 (en) 2015-02-04 2016-08-11 Twist Bioscience Corporation Methods and devices for de novo oligonucleic acid assembly
US9981239B2 (en) 2015-04-21 2018-05-29 Twist Bioscience Corporation Devices and methods for oligonucleic acid library synthesis
GB2557529A (en) 2015-09-18 2018-06-20 Twist Bioscience Corp Oligonucleic acid variant libraries and synthesis thereof
WO2017053450A1 (en) 2015-09-22 2017-03-30 Twist Bioscience Corporation Flexible substrates for nucleic acid synthesis
WO2017095958A1 (en) 2015-12-01 2017-06-08 Twist Bioscience Corporation Functionalized surfaces and preparation thereof
CN116731156A (en) * 2016-03-16 2023-09-12 伊玛提克斯生物技术有限公司 Transfected T cells and T cell receptors for cancer immunotherapy
CN109996876A (en) 2016-08-22 2019-07-09 特韦斯特生物科学公司 The nucleic acid library of de novo formation
WO2018057526A2 (en) 2016-09-21 2018-03-29 Twist Bioscience Corporation Nucleic acid based data storage
ES2916092T3 (en) 2016-12-08 2022-06-28 Immatics Biotechnologies Gmbh New receptors of T lymphocytes and immunotherapies based on their use
DE102016123847B3 (en) 2016-12-08 2018-04-05 Immatics Biotechnologies Gmbh New T cell receptors and their use in immunotherapy
AU2017378492B2 (en) 2016-12-16 2022-06-16 Twist Bioscience Corporation Variant libraries of the immunological synapse and synthesis thereof
US11550939B2 (en) 2017-02-22 2023-01-10 Twist Bioscience Corporation Nucleic acid based data storage using enzymatic bioencryption
CA3056388A1 (en) 2017-03-15 2018-09-20 Twist Bioscience Corporation Variant libraries of the immunological synapse and synthesis thereof
SG11201909153UA (en) * 2017-04-10 2019-10-30 Immatics Biotechnologies Gmbh Peptides and combination thereof for use in the immunotherapy against cancers
WO2018231864A1 (en) 2017-06-12 2018-12-20 Twist Bioscience Corporation Methods for seamless nucleic acid assembly
WO2018231872A1 (en) 2017-06-12 2018-12-20 Twist Bioscience Corporation Methods for seamless nucleic acid assembly
SG11202002194UA (en) 2017-09-11 2020-04-29 Twist Bioscience Corp Gpcr binding proteins and synthesis thereof
CN111433222A (en) * 2017-10-12 2020-07-17 得克萨斯大学体系董事会 T cell receptors for immunotherapy
KR20240024357A (en) 2017-10-20 2024-02-23 트위스트 바이오사이언스 코포레이션 Heated nanowells for polynucleotide synthesis
KR20200106067A (en) 2018-01-04 2020-09-10 트위스트 바이오사이언스 코포레이션 DNA-based digital information storage
GB201803750D0 (en) 2018-03-08 2018-04-25 Immunocore Ltd Method
WO2019196088A1 (en) * 2018-04-13 2019-10-17 Syz Cell Therapy Co. Methods of obtaining tumor-specific t cell receptors
EP3814497A4 (en) 2018-05-18 2022-03-02 Twist Bioscience Corporation Polynucleotides, reagents, and methods for nucleic acid hybridization
JP2021536578A (en) * 2018-09-14 2021-12-27 イマティクス バイオテクノロジーズ ゲーエムベーハー Methods for High Throughput Peptide-MHC Affinity Screening for TCR Ligands
CN113785057A (en) 2019-02-26 2021-12-10 特韦斯特生物科学公司 Variant nucleic acid libraries for antibody optimization
CA3131689A1 (en) 2019-02-26 2020-09-03 Twist Bioscience Corporation Variant nucleic acid libraries for glp1 receptor
US20200297768A1 (en) 2019-03-19 2020-09-24 Immatics US, Inc. Cd28 t cell cultures, compositions, and methods of using thereof
DE102019108125B4 (en) 2019-03-28 2022-02-03 Immatics US, Inc. CD28 T-CELL CULTURES, COMPOSITIONS AND METHODS OF USE
CN111748028A (en) * 2019-03-29 2020-10-09 天津亨佳生物科技发展有限公司 Specific T cell receptor aiming at EGFR L858R gene mutation and application thereof
CN111748029B (en) * 2019-03-29 2022-12-13 苏州蓝马医疗技术有限公司 Specific T cell receptor aiming at EGFR L858R gene mutation and application thereof
SG11202111973RA (en) * 2019-05-08 2021-11-29 Medigene Immunotherapies Gmbh Engineered t cells
CN113874516A (en) 2019-05-27 2021-12-31 伊玛提克斯美国公司 Viral vectors and their use in cell adoptive therapy
WO2020257288A2 (en) * 2019-06-18 2020-12-24 Regeneron Pharmaceuticals, Inc. Mage-a4 t cell receptors and methods of use thereof
AU2020298294A1 (en) 2019-06-21 2022-02-17 Twist Bioscience Corporation Barcode-based nucleic acid sequence assembly
CN110357953B (en) * 2019-07-17 2022-05-03 深圳市因诺转化医学研究院 TCR recognizing human cytomegalovirus pp65 antigen
US20210032370A1 (en) 2019-08-02 2021-02-04 Immatics Biotechnologies Gmbh Recruiting agent further binding an mhc molecule
DE102019121007A1 (en) 2019-08-02 2021-02-04 Immatics Biotechnologies Gmbh Antigen binding proteins that specifically bind to MAGE-A
KR20230012465A (en) 2020-02-24 2023-01-26 이매틱스 유에스 인코포레이티드 Methods for Expanding T Cells to Treat Cancer and Related Malignancies
DE102020111571A1 (en) 2020-03-11 2021-09-16 Immatics US, Inc. WPRE MUTANT CONSTRUCTS, COMPOSITIONS, AND RELATED PROCEDURES
TW202227616A (en) 2020-08-21 2022-07-16 美商英麥提克斯股份有限公司 Methods for isolating cd8+ selected t cells
WO2022075784A1 (en) * 2020-10-07 2022-04-14 연세대학교 산학협력단 T cell receptor, immune cell comprising t cell receptor, and method using same
KR20230135589A (en) 2020-12-31 2023-09-25 이매틱스 유에스 인코포레이티드 CD8 polypeptides, compositions and methods of use thereof
DE102021100038A1 (en) 2020-12-31 2022-06-30 Immatics US, Inc. MODIFIED CD8 POLYPEPTIDES, COMPOSITIONS AND METHODS OF USE THEREOF
CN115975003B (en) * 2021-03-09 2024-01-26 科士华(南京)生物技术有限公司 TCR, polypeptide, expression vector, host cell, pharmaceutical composition and TCR obtaining method
EP4326751A1 (en) * 2021-04-21 2024-02-28 The United States of America, as represented by the Secretary, Department of Health and Human Services Hla class i-restricted t cell receptors against ras with q61k mutation
BR112023022975A2 (en) 2021-05-05 2024-01-23 Immatics Biotechnologies Gmbh IMPROVED BMA031 ANTIGEN BINDING POLYPEPTIDES
CN113337514B (en) * 2021-08-05 2021-10-29 卡瑞济(北京)生命科技有限公司 TCR expression constructs and methods of making and using the same
WO2023044488A1 (en) 2021-09-20 2023-03-23 Immatics US, Inc. Monocyte depletion of t cells populations for t-cell therapy
CN113773378B (en) * 2021-10-14 2023-11-03 深圳大学总医院 T cell receptor and application thereof
US20230192886A1 (en) 2021-11-08 2023-06-22 Immatics Biotechnologies Gmbh Adoptive cell therapy combination treatment and compositions thereof
US20230142468A1 (en) 2021-11-08 2023-05-11 Immatics US, Inc. Methods for generating cell spheroids
WO2023137471A1 (en) 2022-01-14 2023-07-20 Tune Therapeutics, Inc. Compositions, systems, and methods for programming t cell phenotypes through targeted gene activation
WO2023137472A2 (en) 2022-01-14 2023-07-20 Tune Therapeutics, Inc. Compositions, systems, and methods for programming t cell phenotypes through targeted gene repression
WO2023148494A1 (en) * 2022-02-03 2023-08-10 University College Cardiff Consultants Limited Novel t-cell receptor
WO2023183758A2 (en) * 2022-03-19 2023-09-28 Regeneron Pharmaceuticals, Inc. Multispecific molecules targeting cd3 and mage-a4 and uses thereof
US20230348548A1 (en) 2022-04-28 2023-11-02 Immatics US, Inc. Membrane-bound il-15, cd8 polypeptides, cells, compositions, and methods of using thereof
US20240066127A1 (en) 2022-04-28 2024-02-29 Immatics US, Inc. Il-12 polypeptides, il-15 polypeptides, il-18 polypeptides, cd8 polypeptides, compositions, and methods of using thereof
WO2023212691A1 (en) 2022-04-28 2023-11-02 Immatics US, Inc. DOMINANT NEGATIVE TGFβ RECEPTOR POLYPEPTIDES, CD8 POLYPEPTIDES, CELLS, COMPOSITIONS, AND METHODS OF USING THEREOF
US20230355678A1 (en) 2022-05-05 2023-11-09 Immatics US, Inc. Methods for improving t cell efficacy
WO2023250168A2 (en) * 2022-06-24 2023-12-28 Amgen Inc. Magea4 specific t cell receptors
WO2024036166A1 (en) * 2022-08-08 2024-02-15 The University Of North Carolina At Chapel Hill Bioorthogonal t cell receptor molecules and methods of making and using the same
WO2024064642A2 (en) 2022-09-19 2024-03-28 Tune Therapeutics, Inc. Compositions, systems, and methods for modulating t cell function

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP5276846B2 (en) 2005-09-13 2013-08-28 国立大学法人三重大学 Vector having nucleic acid encoding T cell receptor inserted therein and cell expressing said receptor
WO2008053573A1 (en) 2006-10-30 2008-05-08 National University Corporation Hokkaido University Remedy for malignant neoplasm
ME02810B (en) 2010-09-20 2018-01-20 Biontech Cell & Gene Therapies Gmbh Antigen-specific t cell receptors and t cell epitopes
PE20141271A1 (en) * 2011-04-01 2014-10-08 Sloan Kettering Inst Cancer T-CELL RECEPTOR TYPE ANTIBODIES SPECIFIC TO A WT1 PEPTIDE PRESENTED BY HLA-A2
AU2012302778B2 (en) * 2011-08-31 2016-11-24 Mie University Vaccine preparation for cancer treatment
WO2013057596A1 (en) 2011-10-21 2013-04-25 Atena Srl Anatomic cushion accumulator for thermal treatment with heat or cold
GB2508414A (en) * 2012-11-30 2014-06-04 Max Delbrueck Centrum Tumour specific T cell receptors (TCRs)
EP3572510B1 (en) 2013-11-21 2022-09-21 Repertoire Genesis Incorporation T cell receptor and b cell receptor repertoire analysis system, and use of same in treatment and diagnosis
US10202640B2 (en) * 2014-05-07 2019-02-12 The Board Of Trustees Of The Leland Stanford Junior University Single cell analysis of T cells using high-throughput multiplex amplification and deep sequencing

Also Published As

Publication number Publication date
EP3430030B1 (en) 2023-12-20
EA201892021A1 (en) 2019-02-28
TWI764886B (en) 2022-05-21
MX2018011225A (en) 2018-11-22
AU2021204753A1 (en) 2021-08-05
GB201604492D0 (en) 2016-04-27
CA3017502A1 (en) 2017-09-21
KR20210063486A (en) 2021-06-01
KR102457504B1 (en) 2022-10-20
JP7340127B2 (en) 2023-09-07
MA43720A (en) 2018-11-28
US20170267738A1 (en) 2017-09-21
AU2017235467B2 (en) 2021-04-08
AU2017235467A1 (en) 2018-11-01
TW201736396A (en) 2017-10-16
MA43330B1 (en) 2020-06-30
US10538573B2 (en) 2020-01-21
KR20180118783A (en) 2018-10-31
CR20180492A (en) 2019-01-31
JP2019511222A (en) 2019-04-25
CN108884136A (en) 2018-11-23
CN108884136B (en) 2023-03-17
MA43330A1 (en) 2019-07-31
WO2017158103A1 (en) 2017-09-21
KR102259109B1 (en) 2021-06-01
MY189042A (en) 2022-01-21
EP3430030A1 (en) 2019-01-23

Similar Documents

Publication Publication Date Title
SG11201807868VA (en) Transfected t-cells and t-cell receptors for use in immunotherapy against cancers
SG11201807590SA (en) Transfected t-cells and t-cell receptors for use in immunotherapy against cancers
SG11201806905UA (en) Peptides and combination of peptides for use in immunotherapy against non-small cell lung cancer and other cancers
SG11201807300PA (en) Uterine cancer treatments
SG11201806951TA (en) Peptides, combination of peptides, and cell based medicaments for use in immunotherapy against urinary bladder cancer and other cancers
SG11201900955VA (en) T cell receptors and immune therapy using the same
SG11201806577UA (en) Novel peptides and combination of peptides for use in immunotherapy against nhl and other cancers
SG11201908023YA (en) T cell receptors and immune therapy using the same against prame positive cancers
SG11201906198PA (en) Novel peptides and combination of peptides for use in immunotherapy against ovarian cancer and other cancers
SG11201801384YA (en) Peptides and combination of peptides for use in immunotherapy against breast cancer and other cancers
SG11201801670YA (en) Novel peptides and combination of peptides for use in immunotherapy against cll and other cancers
SG11201801756WA (en) Novel peptides and combination of peptides for use in immunotherapy against various cancers
SG11201908527SA (en) High affinity mage-a1-specific tcrs and uses thereof
SG11201909153UA (en) Peptides and combination thereof for use in the immunotherapy against cancers
SG11201808783XA (en) Cd80 variant immunomodulatory proteins and uses thereof
SG11201907870VA (en) Compositions and methods for inhibition of lineage specific proteins
SG11201903021WA (en) Anti-human 4-1 bb antibodies and use thereof
SG11201806150RA (en) Psma and cd3 bispecific t cell engaging antibody constructs
SG11201809781PA (en) Novel peptides, combination of peptides as targets and for use in immunotherapy against gallbladder cancer and cholangiocarcinoma and other cancers
SG11201807279QA (en) Binding proteins and methods of use thereof
SG11201808710UA (en) Novel immunogenic cd1d binding peptides
SG11201810933QA (en) Anti-c5 antibodies and uses thereof
SG11201804839WA (en) Bispecific molecules having immunoreactivity with pd-1 and ctla-4, and methods of use thereof
SG11201907580SA (en) Combination therapies for treatment of bcma-related cancers and autoimmune disorders
SG11201810697QA (en) Chimeric antigen receptor and car-t cells that bind bcma